查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
前列腺癌的预防和治疗：各种技术和全球市场
市场调查报告书
商品编码
1420241

前列腺癌的预防和治疗：各种技术和全球市场

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
出版日期: | 出版商: BCC Research | 英文 157 Pages | 商品交期: 最快1-2个工作天内

价格

全球前列腺癌护理市场规模预计将从 2023 年的 379 亿美元成长到年终的564 亿美元，预测期内复合年增长率为 8.3%。

全球前列腺癌药物市场规模预计将从2023年的175亿美元成长到年终的296亿美元，预测期内复合年增长率为11.0%。此外，摄护腺癌筛检和检测市场规模预计将从2023年的150亿美元成长到年终的198亿美元，复合年增长率为5.8%。

本报告调查了全球前列腺癌护理市场，并提供了市场概况、疾病和治疗概述、市场影响因素分析、市场规模趋势和预测、各个细分市场和地区的详细分析、技术趋势和管道。它总结了线路分析、竞争形势、主要企业简介等。

目录

第一章简介

第 2 章摘要/亮点

第三章市场概况

  • 癌症概述
  • 摄护腺癌
  • 前列腺癌的生物学
  • 症状
  • 筛检
  • 诊断
  • 局限性前列腺癌
  • 转移性前列腺癌
  • 追踪观察或监测治疗
  • 治疗
  • 结论

第四章市场动态

  • 概述
  • 市场驱动因素
  • 摄护腺癌发生率增加
  • 主动监测和筛检
  • 个人化治疗
  • 核准治疗转移性阉割抗性前列腺癌
  • 合作和授权协议
  • 市场挑战
  • 独占期到期和一般化
  • 缺乏医疗设施和其他资源
  • 市场机会

第五章筛检与诊断市场：按测试类型

  • 市场概况
  • 生物标记测试
  • PSA测试
  • PSA 测试的局限性
  • PSA 升高情况​​下早期检测前列腺癌的生物标记测试
  • 直肠指检
  • DRE 限制
  • 摄护腺切片检查
  • 摄护腺癌分级（格里森评分）
  • 前列腺上皮内瘤变
  • 异型性微腺泡增殖
  • 增生性发炎萎缩
  • 前列腺导管内癌
  • 摄护腺切片检查的局限性
  • 前列腺癌影像技术
  • 前列腺癌筛检/诊断市场（按测试类型）
  • 生物标记测试
  • DRE
  • 摄护腺切片检查

第六章 药品市场：依药品类型

  • 市场概况
  • 荷尔蒙治疗
  • 雄性激素剥夺疗法
  • 抗雄性激素治疗
  • 荷尔蒙疗法在前列腺癌治疗的应用
  • 标靶治疗
  • PARP抑制剂
  • 放射配体治疗
  • 小分子标靶药物
  • 单株抗体
  • 化疗
  • 免疫疗法
  • 市场收益：按药物类型
  • 荷尔蒙治疗
  • 标靶治疗
  • 免疫疗法
  • 化疗

第七章手术和放射治疗市场：依治疗类型

  • 市场概况
  • 主动监控
  • 根治性切除术
  • 机械人前列腺切除
  • 根治性切除术
  • 腹腔镜切除术
  • 根治性切除术的市场收益
  • 放射治疗
  • 体外放射放射线治疗
  • 近距离放射
  • 合併放射线治疗
  • 放射治疗设备市场收益

第八章区域市场细分

  • 市场概况
  • 市场收益：按地区
  • 北美洲
  • 市场收益：依产品类型
  • 欧洲
  • 市场收益：依产品类型
  • 亚太地区
  • 市场收益：依产品类型
  • 其他地区
  • 市场收益：依产品类型

第九章 新技术与新进展

  • 概述
  • 液体活体组织切片
  • 多参数磁振造影
  • 同源重组修復基因突变
  • 先进的放射治疗技术
  • 人工智慧和机器学习

第10章管道分析

  • 概述
  • 按公司

第十一章 竞争讯息

  • 概述
  • 筛检/诊断市场
  • 放射治疗设备市场
  • 医药市场

第十二章 公司简介

  • ABBOTT
  • ACCURAY INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BAYER AG
  • DANAHER CORP.
  • DENDREON PHARMACEUTICALS LLC
  • ELEKTA
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES INC.
  • PFIZER INC.
  • SANOFI
  • SIEMENS HEALTHINEERS AG

第十三章附录：简称

Product Code: PHM113C

Highlights:

The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.

The global market for prostate cancer pharmaceuticals is expected to grow from $17.5 billion in 2023 to $29.6 billion by the end of 2028, at a CAGR of 11.0% from 2023 through 2028.

The global market for prostate cancer screening and detection is expected to grow from $15.0 billion in 2023 to $19.8 billion by the end of 2028, at a CAGR of 5.8% from 2023 through 2028.

Report Scope:

This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report.

Report Includes:

  • 31 data tables and 63 additional tables
  • An overview of the global market for the technologies for prevention and treatment of prostate cancer
  • Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region
  • Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas
  • Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations
  • Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer
  • Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer
  • Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios
  • Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer
  • Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies
  • Profiles of leading market participants

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • What's New in this Update?
  • Methodology and Information Sources
  • Geographic Breakdown
  • Segmentation Breakdown

Chapter 2 Summary and Highlights

  • Market Outlook
  • Market Summary

Chapter 3 Market Overview

  • Overview of Cancer
  • Prostate Cancer
  • Biology of Prostate Cancer
  • Symptoms
  • Screening
  • Diagnosis
  • Localized Prostate Cancer
  • Metastatic Prostate Cancer
  • Watchful Waiting or Active Surveillance
  • Treatment
  • Conclusions

Chapter 4 Market Dynamics

  • Overview
  • Market Drivers
  • Increasing Prevalence of Prostate Cancer
  • Active Surveillance and Screening
  • Personalized Care
  • Approvals for Metastatic Castration-Resistant Prostate Cancer
  • Collaborations and Licensing Agreements
  • Market Challenges
  • Loss of Exclusivity and Genericization
  • Shortage of Care Providers and Other Resources
  • Market Opportunities

Chapter 5 Screening and Diagnosis Market by Test Type

  • Market Overview
  • Biomarker Tests
  • PSA Tests
  • Limitations of PSA Tests
  • Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings
  • Digital Rectal Exam
  • Limitations of DREs
  • Prostate Biopsy
  • Grade (Gleason Score) of Prostate Cancer
  • Prostatic Intraepithelial Neoplasia
  • Atypical Small Acinar Proliferation
  • Proliferative Inflammatory Atrophy
  • Intraductal Carcinoma of the Prostate
  • Limitations of Prostate Biopsies
  • Imaging Technologies for Prostate Cancer
  • Market for Prostate Cancer Screening/Diagnosis, by Test Type
  • Biomarker Tests
  • DREs
  • Prostate Biopsies

Chapter 6 Pharmaceuticals Market by Drug Type

  • Market Overview
  • Hormone Therapy
  • Androgen Deprivation Therapy
  • Antiandrogen Therapies
  • Hormone Therapy Uses in Prostate Cancer Treatment
  • Targeted Therapy
  • PARP Inhibitors
  • Radioligand Therapies
  • Small Molecule Targeted Agents
  • Monoclonal Antibodies
  • Chemotherapy
  • Immunotherapy
  • Market Revenue, by Drug Type
  • Hormone Therapy
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy

Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type

  • Market Overview
  • Active Surveillance
  • Radical Prostatectomy
  • Robotic Prostatectomy
  • Open Radical Prostatectomy
  • Laparoscopic Prostatectomy
  • Radical Prostatectomy Market Revenue
  • Radiation Therapy
  • External Beam Radiation Therapy
  • Brachytherapy
  • Combined Radiation Therapy
  • Radiation Therapy Device Market Revenue

Chapter 8 Market Breakdown by Region

  • Market Overview
  • Market Revenue, by Region
  • North America
  • Market Revenue, by Product Type
  • Europe
  • Market Revenue, by Product Type
  • Asia-Pacific
  • Market Revenue, by Product Type
  • Rest of the World (RoW)
  • Market Revenue, by Product Type

Chapter 9 Emerging Technologies and Developments

  • Overview
  • Liquid Biopsy
  • Multiparametric MRI
  • Homologous Recombination Repair Gene Mutation
  • Advanced Radiotherapy Techniques
  • AI and Machine Learning

Chapter 10 Pipeline Analysis

  • Overview
  • By Company

Chapter 11 Competitive Intelligence

  • Overview
  • Screening and Diagnosis Market
  • Market for Radiation Therapy Devices
  • Pharmaceuticals Market

Chapter 12 Company Profiles

  • ABBOTT
  • ACCURAY INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BAYER AG
  • DANAHER CORP.
  • DENDREON PHARMACEUTICALS LLC
  • ELEKTA
  • F. HOFFMANN-LA ROCHE LTD.
  • JOHNSON & JOHNSON SERVICES INC.
  • PFIZER INC.
  • SANOFI
  • SIEMENS HEALTHINEERS AG

Chapter 13 Appendix: Abbreviations

List of Tables

  • Summary Table : Global Market for Prostate Cancer Care, by Type, Through 2028
  • Table 1 : Four Stages of Prostate Cancer
  • Table 2 : Prostate Cancer: Local and Metastatic Symptoms
  • Table 3 : Current Prostate Cancer Treatment Options
  • Table 4 : Prostate Cancer: Major Points
  • Table 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 to 2040
  • Table 6 : Key Biomarkers for Prostate Cancer
  • Table 7 : First-Time Generic Drug Approvals for Prostate Cancer, 2021 to November 2023
  • Table 8 : ACS, NCCN and USPSTF Guidelines on PSA Screening Tests
  • Table 9 : Additional Biomarker Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
  • Table 10 : NCCN and USPSTF Guidelines on Use of DRE for Prostate Cancer Screening
  • Table 11 : Imaging Technologies for Prostate Cancer
  • Table 12 : Prostate Cancer Screening and Diagnostic Methods
  • Table 13 : Global Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
  • Table 14 : Hormone Therapy Drugs Approved for Prostate Cancer Treatment
  • Table 15 : PARP Inhibitors Approved for Prostate Cancer Treatment
  • Table 16 : Radioligand Drugs Approved for Prostate Cancer Treatment
  • Table 17 : Chemotherapy Drugs Approved for Prostate Cancer Treatment
  • Table 18 : Immunotherapy Approved for Prostate Cancer Treatment
  • Table 19 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, Through 2028
  • Table 20 : Global Market for Hormone Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
  • Table 21 : Global Market for Targeted Therapy Drugs for Prostate Cancer, by Drug Type, Through 2028
  • Table 22 : Treatment Options for Prostate Cancer
  • Table 23 : Advantages and Disadvantages of Radical Prostatectomy
  • Table 24 : Global Market for Radical Prostatectomy, Through 2028
  • Table 25 : Comparison of Low- and High-Dose Radiation Therapy
  • Table 26 : Comparison of EBRT and Brachytherapy
  • Table 27 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, Through 2028
  • Table 28 : Advances in EBRT
  • Table 29 : Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region, Through 2028
  • Table 30 : North American Market for Prostate Cancer Care, by Product Type, Through 2028
  • Table 31 : North American Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
  • Table 32 : Europe: Prostate Cancer Incidence, Mortality and Prevalence, 2020
  • Table 33 : European Market for Prostate Cancer Care, by Product Type, Through 2028
  • Table 34 : European Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
  • Table 35 : Worldwide Number of New Prostate Cancer Cases, by Region, 2020, 2030, 2040
  • Table 36 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, Through 2028
  • Table 37 : Asia-Pacific Market for Prostate Cancer Screening and Detection, by Test Type, Through 2028
  • Table 38 : RoW Market for Prostate Cancer Care, by Product Type, Through 2028
  • Table 39 : Liquid Biopsy Tests for the Early Detection/Screening of Prostate Cancer in Elevated PSA Settings
  • Table 40 : PARP Inhibitors in Phase 3 Clinical Trials
  • Table 41 : Companies with Two or More Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Company, as of November 2023
  • Table 42 : Prostate Cancer Drugs Pipeline (Phase III Industry Trials)
  • Table 43 : Ranking of Companies in the Market for Biomarker Tests for Prostate Cancer Screening and Diagnosis, 2022
  • Table 44 : Ranking of Companies in the Market for Radiation Therapy Devices for Prostate Cancer, 2022
  • Table 45 : Abbott: Company Snapshot
  • Table 46 : Abbott: Financial Performance, FY 2021 and 2022
  • Table 47 : Abbott: Prostate Cancer Product Portfolio
  • Table 48 : Accuracy Inc.: Company Snapshot
  • Table 49 : Accuracy Inc.: Financial Performance, FY 2022 and 2023
  • Table 50 : Accuray Inc.: Radiotherapy Product Portfolio
  • Table 51 : Accuray Inc.: Recent Developments, 2022-2023
  • Table 52 : Astellas Pharma Inc.: Company Snapshot
  • Table 53 : Astellas Pharma Inc.: Financial Performance, FY 2021 and 2022
  • Table 54 : Astellas Pharma Inc.: Prostate Cancer Drug Portfolio
  • Table 55 : Astellas Pharma Inc.: Recent Developments, 2021-2023
  • Table 56 : AstraZeneca Plc: Company Snapshot
  • Table 57 : AstraZeneca Plc: Financial Performance, FY 2021 and 2022
  • Table 58 : AstraZeneca Plc: Prostate Cancer Drug Portfolio
  • Table 59 : AstraZeneca Plc: Recent Developments, 2022-2023
  • Table 60 : Bayer AG: Company Snapshot
  • Table 61 : Bayer AG: Financial Performance, FY 2021 and 2022
  • Table 62 : Bayer AG: Prostate Cancer Drugs Portfolio
  • Table 63 : Bayer AG: Recent Developments, 2021-2023
  • Table 64 : Danaher Corp.: Company Snapshot
  • Table 65 : Danaher Corp.: Financial Performance, FY 2021 and 2022
  • Table 66 : Danaher Corp.: Prostate Health Product Portfolio
  • Table 67 : Dendreon Pharmaceuticals LLC: Company Snapshot
  • Table 68 : Dendreon Pharmaceuticals LLC: Prostate Cancer Drug Portfolio
  • Table 69 : Elekta: Company Snapshot
  • Table 70 : Elekta: Financial Performance, FY 2022 and 2023
  • Table 71 : Elekta: Radiotherapy Product Portfolio
  • Table 72 : Elekta: Recent Developments, 2021-2023
  • Table 73 : F. Hoffmann-La Roche Ltd.: Company Snapshot
  • Table 74 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2021 and 2022
  • Table 75 : F. Hoffmann-La Roche Ltd.: Product Portfolio
  • Table 76 : F. Hoffmann-La Roche Ltd.: Recent Developments, 2023
  • Table 77 : Johnson & Johnson Services, Inc.: Company Snapshot
  • Table 78 : Johnson & Johnson Services, Inc.: Financial Performance, FY 2021 and 2022
  • Table 79 : Johnson & Johnson Services, Inc.: Prostate Cancer Drug Portfolio
  • Table 80 : Johnson & Johnson Services, Inc.: Recent Developments, 2023
  • Table 81 : Pfizer Inc.: Company Snapshot
  • Table 82 : Pfizer Inc.: Financial Performance, FY 2021 and 2022
  • Table 83 : Pfizer Inc.: Prostate Cancer Drugs Portfolio
  • Table 84 : Pfizer Inc.: Recent Developments, 2022-2023
  • Table 85 : Sanofi: Company Snapshot
  • Table 86 : Sanofi: Financial Performance, FY 2021 and 2022
  • Table 87 : Sanofi: Prostate Cancer Drug Portfolio
  • Table 88 : Sanofi: Recent Developments, 2022
  • Table 89 : Siemens Healthineers: Company Snapshot
  • Table 90 : Siemens Healthineers: Financial Performance, FY 2022 and 2023
  • Table 91 : Siemens Healthineers: Prostate Cancer Product Portfolio
  • Table 92 : Siemens Healthineers: Recent Developments, 2022-2023
  • Table 93 : Abbreviations Used in this Report

List of Figures

  • Summary Figure A : Global Market for Prostate Cancer Care, by Type, 2020-2028
  • Summary Figure B : Global Market Shares of Prostate Cancer Care, by Type, 2022
  • Figure 1 : Cancer Care Spectrum
  • Figure 2 : Prostate Cancer Risk Group
  • Figure 3 : Prostate Cancer Advancements
  • Figure 4 : Prostate Cancer Care Market Dynamics
  • Figure 5 : Estimated Number of New Prostate Cancer Cases, by Region, 2020 and 2040
  • Figure 6 : Share of Prostate Cancer Cases, by Stage
  • Figure 7 : Prostate Cancer Incidence in the U.S.
  • Figure 8 : Cancer Radiotherapy Systems Treatment, by Region, 2021
  • Figure 9 : Prostate Cancer 5-Year Relative Survival Rates
  • Figure 10 : Trends in Oncology
  • Figure 11 : Global Market for Prostate Cancer Screening and Detection, by Test Type, 2020-2028
  • Figure 12 : Global Market Shares of Prostate Cancer Screening and Detection, by Test Type, 2022
  • Figure 13 : Benefits of Immunotherapy
  • Figure 14 : Global Market for Prostate Cancer Pharmaceuticals, by Drug Type, 2020-2028
  • Figure 15 : Global Market Shares of Prostate Cancer Pharmaceuticals, by Drug Type, 2022
  • Figure 16 : Global Market Shares of Hormone Therapy Drugs for Prostate Cancer, by Drug Type, 2022
  • Figure 17 : Global Market Shares of Targeted Therapy Drugs for Prostate Cancer, by Drug Type, 2022
  • Figure 18 : Global Market for Radical Prostatectomy, 2020-2028
  • Figure 19 : Types of Radiation
  • Figure 20 : Global Market for Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2020-2028
  • Figure 21 : Global Market Shares of Radiation Therapy Devices for Prostate Cancer, by Treatment Type, 2022
  • Figure 22 : Snapshot of Global Market for Prostate Cancer Screening, Diagnosis and Treatment, by Region
  • Figure 23 : Global Market Shares of Prostate Cancer Screening, Diagnosis and Treatment, by Region, 2022
  • Figure 24 : Estimated Number of Prostate Cancer Cases in the U.S., Both Sexes, 2020 to 2040
  • Figure 25 : North American Market for Prostate Cancer Care, by Product Type, 2020-2028
  • Figure 26 : European Market for Prostate Cancer Care, by Product Type, 2020-2028
  • Figure 27 : Worldwide Distribution of New Prostate Cancer Cases, by Region, 2020-2040
  • Figure 28 : Asia-Pacific Market for Prostate Cancer Care, by Product Type, 2020-2028
  • Figure 29 : RoW Market for Prostate Cancer Care, by Product Type, 2020-2028
  • Figure 30 : Emerging Technologies in Prostate Cancer Care
  • Figure 31 : Active Clinical Trials in Phase 2 or 3 for Prostate Cancer, by Cancer Type, as of November 2023
  • Figure 32 : Share of Active Clinical Trials in Phase 2 or 3 for Castration-Resistant Prostate Cancer (CRPC), by Cancer Type, as of November 2023
  • Figure 33 : Global Market Share of Prostate Cancer Pharmaceutical, by Company, 2022
  • Figure 34 : Abbott: Revenue Share, by Business Unit, FY 2022
  • Figure 35 : Abbott: Revenue Share, by Region, FY 2022
  • Figure 36 : Accuray Inc.: Revenue Share, by Product Type, FY 2023
  • Figure 37 : Accuray Inc.: Revenue Share, by Region, FY 2023
  • Figure 38 : Astellas Pharma Inc.: Revenue Share, by Product, 2022
  • Figure 39 : Astellas Pharma Inc.: Revenue Share, by Region, 2022
  • Figure 40 : AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
  • Figure 41 : AstraZeneca Plc: Revenue Share, by Region, 2022
  • Figure 42 : Bayer AG: Revenue Share, by Business Segment, 2022
  • Figure 43 : Bayer AG: Revenue Share, by Region, 2022
  • Figure 44 : Danaher Corp.: Market Share, by Business Segment, 2022
  • Figure 45 : Danaher Corp.: Revenue Share, by Region, 2022
  • Figure 46 : Elekta: Revenue Share, by Product Type, 2023
  • Figure 47 : Elekta: Revenue Share, by Region, 2023
  • Figure 48 : F. Hoffmann-La Roche Ltd.: Market Share, by Business Segment, 2022
  • Figure 49 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Region, 2022
  • Figure 50 : Johnson & Johnson Services, Inc.: Revenue Share, by Business Segment, 2022
  • Figure 51 : Johnson & Johnson Services, Inc.: Revenue Share, by Region, 2022
  • Figure 52 : Pfizer Inc.: Revenue Share, by Business Unit, 2022
  • Figure 53 : Pfizer Inc.: Revenue Share, by Region, 2022
  • Figure 54 : Sanofi: Revenue Share, by Global Business Unit, 2022
  • Figure 55 : Sanofi: Revenue Share, by Region, 2022
  • Figure 56 : Siemens Healthineers: Revenue Share, by Segment, 2023
  • Figure 57 : Siemens Healthineers: Revenue Share, by Region, 2023